USPSTF releases draft recommendations on aspirin use in primary CVD prevention
DALLAS, Tuesday, October 12, 2021 — The U.S. Preventive Services Task Force (USPSTF) has released draft recommendations on aspirin therapy for the primary prevention of cardiovascular disease in adults.
The draft recommendations are posted for public comment until November 8, 2021 and will be reviewed by the USPSTF for final decision. USPTSF is an independent, volunteer panel of medical experts focused on improving the health of people nationwide by making evidence-based recommendations on effective ways to prevent disease and prolong life.
The following statement reflects the views of the American Heart Association/American Stroke Association.
According to the Association's volunteer President Donald M. Lloyd-Jones, M.D., Sc.M., FAHA, "As detailed in the American College of Cardiology/American Heart Association's 2019 primary prevention recommendations, recent large trials indicate that, in the current environment, the overall benefit of aspirin is small -- in most adults the benefit of protection against heart attacks and strokes is offset by the potential risk of bleeding caused by aspirin. As a result, aspirin should be used rarely to help prevent heart attacks and stroke among adults ages 40-70 without known cardiovascular disease.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.